Stuart Allan

List of Publications by Year
in descending order

157 papers	11,809 citations	28190 55 h-index	29081 104 g-index
164 all docs	164 docs citations	164 times ranked	16644 citing authors

#	Article	IF	Citations
1	Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, 001-010.	0.4	4
2	Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models. Blood, 2022, 139, 1575-1587.	0.6	10
3	Does previous stroke modify the relationship between inflammatory biomarkers and clinical endpoints in CKD patients?. BMC Nephrology, 2022, 23, 38.	0.8	1
4	Zebrafish drug screening identifies candidate therapies for neuroprotection after spontaneous intracerebral haemorrhage. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	8
5	Do Concentration or Activity of Selenoproteins Change in Acute Stroke Patients? A Systematic Review and Meta-Analyses. Cerebrovascular Diseases, 2022, 51, 461-472.	0.8	1
6	Itaconate and fumarate derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in macrophages. Immunology, 2022, 165, 460-480.	2.0	33
7	Systematic review: Association between circulating microRNA expression & stroke. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 935-951.	2.4	12
8	Re-directing nanomedicines to the spleen: A potential technology for peripheral immunomodulation. Journal of Controlled Release, 2022, 350, 60-79.	4.8	9
9	Functionally linked potassium channel activity in cerebral endothelial and smooth muscle cells is compromised in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	15
10	Revisiting promising preclinical intracerebral hemorrhage studies to highlight repurposable drugs for translation. International Journal of Stroke, 2021, 16, 123-136.	2.9	8
11	Influence of metabolic syndrome on post-stroke outcome, angiogenesis and vascular function in old rats determined by dynamic contrast enhanced MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1692-1706.	2.4	9
12	A hyperacute immune map of ischaemic stroke patients reveals alterations to circulating innate and adaptive cells. Clinical and Experimental Immunology, 2021, 203, 458-471.	1.1	7
13	Global proteomic analysis of extracellular matrix in mouse and human brain highlights relevance to cerebrovascular disease. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2423-2438.	2.4	14
14	Systemic infection exacerbates cerebrovascular dysfunction in Alzheimerâ€™s disease. Brain, 2021, 144, 1869-1883.	3.7	32
15	Glyceryl trinitrate for the treatment of ischaemic stroke: Determining efficacy in rodent and ovine species for enhanced clinical translation. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3248-3259.	2.4	4
16	Regenerative Potential of Hydrogels for Intracerebral Hemorrhage: Lessons from Ischemic Stroke and Traumatic Brain Injury Research. Advanced Healthcare Materials, 2021, 10, e2100455.	3.9	13
17	Cardiovascular comorbidities, inflammation, and cerebral small vessel disease. Cardiovascular Research, 2021, 117, 2575-2588.	1.8	22
18	Characterisation of microvessel blood velocity and segment length in the brain using multi-diffusion-time diffusion-weighted MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 0271678X2097852.	2.4	3

#	Article	IF	Citations
19	Ligature-induced periodontitis induces systemic inflammation but does not alter acute outcome after stroke in mice. International Journal of Stroke, 2020, 15, 175-187.	2.9	18
20	Stroke Induces Prolonged Changes in Lipid Metabolism, the Liver and Body Composition in Mice. Translational Stroke Research, 2020, 11, 837-850.	2.3	19
21	A Multi-Model Pipeline for Translational Intracerebral Haemorrhage Research. Translational Stroke Research, 2020, 11, 1229-1242.	2.3	16
22	Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study. BMJ Open, 2020, 10, e041983.	0.8	14
23	UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1402-1414.	2.4	4
24	Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatology, The, 2020, 2, e379-e381.	2.2	47
25	Preceding infection and risk of stroke: An old concept revived by the COVID-19 pandemic. International Journal of Stroke, 2020, 15, 722-732.	2.9	40
26	Therapeutic potential of extracellular vesicles in preclinical stroke models: a systematic review and meta-analysisTherapeutic potential of extracellular vesicles in preclinical stroke models: a systematic review and meta-analysis. BMJ Open Science, 2020, 44, e100047.	0.8	12
27	Systemic conditioned medium treatment from interleukin-1 primed mesenchymal stem cells promotes recovery after stroke. Stem Cell Research and Therapy, 2020, 11, 32.	2.4	28
28	Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture. Immunology, 2020, 161, 39-52.	2.0	12
29	Improved reperfusion following alternative surgical approach for experimental stroke in mice. F1000Research, 2020, 9, 188.	0.8	5
30	Improved reperfusion following alternative surgical approach for experimental stroke in mice. F1000Research, 2020, 9, 188.	0.8	3
31	Selective Liposomal Transport through Blood Brain Barrier Disruption in Ischemic Stroke Reveals Two Distinct Therapeutic Opportunities. ACS Nano, 2019, 13, 12470-12486.	7.3	66
32	Using Zebrafish Larvae to Study the Pathological Consequences of Hemorrhagic Stroke. Journal of Visualized Experiments, 2019, , .	0.2	11
33	Extent of Ischemic Brain Injury After Thrombotic Stroke Is Independent of the NLRP3 (NACHT, LRR and) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	38
34	Interleukin-1 mediates ischaemic brain injury via distinct actions on endothelial cells and cholinergic neurons. Brain, Behavior, and Immunity, 2019, 76, 126-138.	2.0	48
35	Vascular dysfunctionâ€"The disregarded partner of Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 158-167.	0.4	454
36	Acute high-fat feeding leads to disruptions in glucose homeostasis and worsens stroke outcome. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1026-1037.	2.4	27

#	Article	IF	Citations
37	Microglial Priming as Trained Immunity in the Brain. Neuroscience, 2019, 405, 47-54.	1.1	68
38	Pentraxin 3 regulates neutrophil infiltration to the brain during neuroinflammation. AMRC Open Research, 2019, 1, 10.	1.7	9
39	Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Research, 2019, 8, 1039.	0.8	6
40	Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Research, 2019, 8, 1039.	0.8	5
41	Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses. Scientific Reports, 2018, 8, 5667.	1.6	27
42	Neutrophil infiltration to the brain is plateletâ€dependent, and is reversed by blockade of platelet GPIb<i>Î±</i>. Immunology, 2018, 154, 322-328.	2.0	36
43	SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke). Stroke, 2018, 49, 1210-1216.	1.0	137
44	Assessing Inflammation in Acute Intracerebral Hemorrhage with PK11195 PET and Dynamic Contrast-Enhanced MRI. , 2018, 28, 158-161.		15
45	Small, Thin Graphene Oxide Is Anti-inflammatory Activating Nuclear Factor Erythroid 2-Related Factor 2 <i>via</i> Metabolic Reprogramming. ACS Nano, 2018, 12, 11949-11962.	7.3	43
46	Stroke: The past, present and future. Brain and Neuroscience Advances, 2018, 2, 239821281881068.	1.8	21
47	Pentraxin 3 promotes long-term cerebral blood flow recovery, angiogenesis, and neuronal survival after stroke. Journal of Molecular Medicine, 2018, 96, 1319-1332.	1.7	24
48	The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1276-1292.	2.4	184
49	Targeting the IL33â€"NLRP3 axis improves therapy for experimental cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7404-7409.	3.3	37
50	Changes in the secretome of tri-dimensional spheroid-cultured human mesenchymal stem cells in vitro by interleukin-1 priming. Stem Cell Research and Therapy, 2018, 9, 11.	2.4	74
51	Using zebrafish larval models to study brain injury, locomotor and neuroinflammatory outcomes following intracerebral haemorrhage. F1000Research, 2018, 7, 1617.	0.8	16
52	Using zebrafish larval models to study brain injury, locomotor and neuroinflammatory outcomes following intracerebral haemorrhage. F1000Research, 2018, 7, 1617.	0.8	18
53	Generation of Human Mesenchymal Stem Cell 3D Spheroids Using Low-binding Plates. Bio-protocol, 2018, 8, .	0.2	17
54	Translational models for vascular cognitive impairment: a review including larger species. BMC Medicine, 2017, 15, 16.	2.3	71

#	Article	IF	Citations
55	A brain in flame; do inflammasomes and pyroptosis influence stroke pathology?. Brain Pathology, 2017, 27, 205-212.	2.1	119
56	Boron-Based Inhibitors of the NLRP3 Inflammasome. Cell Chemical Biology, 2017, 24, 1321-1335.e5.	2.5	77
57	The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments). Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3488-3517.	2.4	128
58	Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro. Stem Cell Research and Therapy, 2017, 8, 79.	2.4	168
59	Reparative effects of interleukin-1 receptor antagonist in young and aged/co-morbid rodents after cerebral ischemia. Brain, Behavior, and Immunity, 2017, 61, 117-126.	2.0	64
60	A quantitative brain map of experimental cerebral malaria pathology. PLoS Pathogens, 2017, 13, e1006267.	2.1	73
61	Isolation and Cultivation of Primary Brain Endothelial Cells from Adult Mice. Bio-protocol, 2017, 7, .	0.2	34
62	Decreased haemodynamic response and decoupling of cortical gamma-band activity and tissue oxygen perfusion after striatal interleukin-1 injection. Journal of Neuroinflammation, 2016, 13, 195.	3.1	6
63	Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke. Stroke, 2016, 47, 1312-1318.	1.0	36
64	Development & automation of a novel [18F]F prosthetic group, 2-[18F]-fluoro-3-pyridinecarboxaldehyde, and its application to an amino(oxy)-functionalised AÎ² peptide. Applied Radiation and Isotopes, 2016, 116, 120-127.	0.7	8
65	Characterization of a conditional interleukinâ€1 receptor 1 mouse mutant using the Cre/LoxP system. European Journal of Immunology, 2016, 46, 912-918.	1.6	25
66	Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimerâ€™s disease in rodent models. Nature Communications, 2016, 7, 12504.	5.8	328
67	Mitochondrial Abnormalities and Synaptic Loss Underlie Memory Deficits Seen in Mouse Models of Obesity and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 915-932.	1.2	55
68	Interleukin-1 in Stroke. Stroke, 2016, 47, 2160-2167.	1.0	104
69	Systemic inflammation affects reperfusion following transient cerebral ischaemia. Experimental Neurology, 2016, 277, 252-260.	2.0	23
70	A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 596-605.	2.4	61
71	<scp>IL</scp>â€1Î± and inflammasomeâ€independent <scp>IL</scp>â€1Î² promote neutrophil infiltration following alum vaccination. FEBS Journal, 2016, 283, 9-24.	2.2	60
72	Emerging roles of the acute phase protein pentraxin-3 during central nervous system disorders. Journal of Neuroimmunology, 2016, 292, 27-33.	1.1	21

#	Article	IF	Citations
73	Interleukinâ€1 as a pharmacological target in acute brain injury. Experimental Physiology, 2015, 100, 1488-1494.	0.9	26
74	Interleukin-1 and acute brain injury. Frontiers in Cellular Neuroscience, 2015, 9, 18.	1.8	125
75	Acid-dependent Interleukin-1 (IL-1) Cleavage Limits Available Pro-IL-1Î² for Caspase-1 Cleavage. Journal of Biological Chemistry, 2015, 290, 25374-25381.	1.6	13
76	Requirement for interleukinâ€1 to drive brain inflammation reveals tissueâ€specific mechanisms of innate immunity. European Journal of Immunology, 2015, 45, 525-530.	1.6	33
77	Delayed Reperfusion Deficits after Experimental Stroke Account for Increased Pathophysiology. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 277-284.	2.4	37
78	AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4050-4055.	3.3	211
79	Systemic Inflammation Impairs Tissue Reperfusion Through Endothelin-Dependent Mechanisms in Cerebral Ischemia. Stroke, 2014, 45, 3412-3419.	1.0	42
80	Circulating Cytokines and Alarmins Associated with Placental Inflammation in Highâ€Risk Pregnancies. American Journal of Reproductive Immunology, 2014, 72, 422-434.	1.2	63
81	<i>Streptococcus pneumoniae</i> worsens cerebral ischemia via interleukin 1 and platelet glycoprotein IbÎ±. Annals of Neurology, 2014, 75, 670-683.	2.8	50
82	Endogenous Oils Derived From Human Adipocytes Are Potent Adjuvants That Promote IL-1Î±â€"Dependent Inflammation. Diabetes, 2014, 63, 2037-2050.	0.3	38
83	Epilepsy and the inflammasome: Targeting inflammation as a novel therapeutic strategy for seizure disorders. Inflammasome, 2014, 1, .	0.6	7
84	The Acute-Phase Protein PTX3 is an Essential Mediator of Glial Scar Formation and Resolution of Brain Edema after Ischemic Injury. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 480-488.	2.4	73
85	Chitinase-like proteins promote IL-17-mediated neutrophilia in a tradeoff between nematode killing and host damage. Nature Immunology, 2014, 15, 1116-1125.	7.0	187
86	Late-Onset Epilepsy and Occult Cerebrovascular Disease. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 564-570.	2.4	42
87	Variations in inflammation-related genes may be associated with childhood febrile seizure susceptibility. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 457-461.	0.9	16
88	High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice isÂindependent of changes in amyloid and tau pathology. Neurobiology of Aging, 2014, 35, 1821-1832.	1.5	189
89	Long-term functional recovery and compensation after cerebral ischemia in rats. Behavioural Brain Research, 2014, 270, 18-28.	1.2	34
90	Maternal High-Fat Diet Worsens Memory Deficits in the Triple-Transgenic (3xTgAD) Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e99226.	1.1	33

#	Article	IF	Citations
91	Systemic immune activation shapes stroke outcome. Molecular and Cellular Neurosciences, 2013, 53, 14-25.	1.0	67
92	Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in mice. DMM Disease Models and Mechanisms, 2013, 6, 1043-8.	1.2	35
93	Microglia and macrophages differentially modulate cell death after brain injury caused by oxygenâ€glucose deprivation in organotypic brain slices. Glia, 2013, 61, 813-824.	2.5	143
94	Acidosis Drives Damage-associated Molecular Pattern (DAMP)-induced Interleukin-1 Secretion via a Caspase-1-independent Pathway. Journal of Biological Chemistry, 2013, 288, 30485-30494.	1.6	50
95	Surgical manipulation compromises leukocyte mobilization responses and inflammation after experimental cerebral ischemia in mice. Frontiers in Neuroscience, 2013, 7, 271.	1.4	11
96	Interleukinâ€1 Mediates Neuroinflammatory Changes Associated With Dietâ€Induced Atherosclerosis. Journal of the American Heart Association, 2012, 1, e002006.	1.6	38
97	Delayed Administration of Interleukin-1 Receptor Antagonist Reduces Ischemic Brain Damage and Inflammation in Comorbid Rats. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1810-1819.	2.4	122
98	Neutrophil Cerebrovascular Transmigration Triggers Rapid Neurotoxicity through Release of Proteases Associated with Decondensed DNA. Journal of Immunology, 2012, 189, 381-392.	0.4	174
99	Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. DMM Disease Models and Mechanisms, 2012, 5, 823-33.	1.2	89
100	Age-related changes in core body temperature and activity in triple-transgenic Alzheimerâ€™s disease (3xTgAD) mice. DMM Disease Models and Mechanisms, 2012, 6, 160-70.	1.2	52
101	Hypermetabolism in a triple-transgenic mouse model of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 187-193.	1.5	46
102	An Endovascular Perforation Model of Subarachnoid Haemorrhage in Rat Produces Heterogeneous Infarcts that Increase with Blood Load. Translational Stroke Research, 2012, 3, 164-172.	2.3	13
103	Systematic Review and Meta-Analysis of the Efficacy of Statins in Experimental Stroke. International Journal of Stroke, 2012, 7, 150-156.	2.9	20
104	Assessing the contribution of inflammation in models of Alzheimer's disease. Biochemical Society Transactions, 2011, 39, 886-890.	1.6	102
105	Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity, 2011, 25, 1113-1122.	2.0	173
106	Regulation of interleukin-1 in acute brain injury. Trends in Pharmacological Sciences, 2011, 32, 617-622.	4.0	71
107	Experimental Stroke-Induced Changes in the Bone Marrow Reveal Complex Regulation of Leukocyte Responses. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1036-1050.	2.4	61
108	Experimental Intracerebral Hemorrhage: Avoiding Pitfalls in Translational Research. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2135-2151.	2.4	62

#	Article	IF	Citations
109	Interleukin-1 and Stroke: Biomarker, Harbinger of Damage, and Therapeutic Target. Cerebrovascular Diseases, 2011, 32, 517-527.	0.8	103
110	Letter by McColl et al Regarding Article, â€œInfluenza Virus Infection Aggravates Stroke Outcomeâ€. Stroke, 2011, 42, e416; author reply e417.	1.0	3
111	Occult Cerebrovascular Disease and Late-Onset Epilepsy: Could Loss of Neurovascular Unit Integrity Be a Viable Model?. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-7.	0.8	17
112	Platelet interleukin-1Î± drives cerebrovascular inflammation. Blood, 2010, 115, 3632-3639.	0.6	145
113	Tuftsin derivatives of FITC, Tbâ€"DOTA or Gdâ€"DOTA as potential macrophageâ€specific imaging biomarkers. Contrast Media and Molecular Imaging, 2010, 5, 223-230.	0.4	5
114	Interleukin-1 Receptor Antagonist in Animal Models of Stroke: A Fair Summing Up?. Journal of Stroke and Cerebrovascular Diseases, 2010, 19, 512-513.	0.7	4
115	Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. Brain, Behavior, and Immunity, 2010, 24, 708-723.	2.0	251
116	Interleukin-1 Drives Cerebrovascular Inflammation via MAP Kinase-Independent Pathways. Current Neurovascular Research, 2010, 7, 330-340.	0.4	35
117	A Rapid and Transient Peripheral Inflammatory Response Precedes Brain Inflammation after Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1764-1768.	2.4	114
118	Systemic infection, inflammation and acute ischemic stroke. Neuroscience, 2009, 158, 1049-1061.	1.1	280
119	ADAMTS-9 expression is up-regulated following transient middle cerebral artery occlusion (tMCAo) in the rat. Neuroscience Letters, 2009, 452, 252-257.	1.0	17
120	Inflammatory responses in the rat brain in response to different methods of intra-cerebral administration. Journal of Neuroimmunology, 2008, 194, 27-33.	1.1	39
121	Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Molecular and Cellular Neurosciences, 2008, 37, 135-142.	1.0	49
122	Systemic Inflammation Alters the Kinetics of Cerebrovascular Tight Junction Disruption after Experimental Stroke in Mice. Journal of Neuroscience, 2008, 28, 9451-9462.	1.7	286
123	Impaired Adult Neurogenesis in the Dentate Gyrus of a Triple Transgenic Mouse Model of Alzheimer's Disease. PLoS ONE, 2008, 3, e2935.	1.1	314
124	Systemic Inflammatory Stimulus Potentiates the Acute Phase and CXC Chemokine Responses to Experimental Stroke and Exacerbates Brain Damage via Interleukin-1- and Neutrophil-Dependent Mechanisms. Journal of Neuroscience, 2007, 27, 4403-4412.	1.7	320
125	Systemic inflammation and stroke: aetiology, pathology and targets for therapy. Biochemical Society Transactions, 2007, 35, 1163-1165.	1.6	59
126	Proliferating Resident Microglia after Focal Cerebral Ischaemia in Mice. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1941-1953.	2.4	301

#	Article	IF	Citations
127	Collapsin response mediator proteinâ€2 hyperphosphorylation is an early event in Alzheimerâ€™s disease progression. Journal of Neurochemistry, 2007, 103, 1132-1144.	2.1	158
128	Neuroinflammation in Parkinsonâ€™s patients and MPTP-treated mice is not restricted to the nigrostriatal system: Microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Experimental Gerontology, 2007, 42, 762-771.	1.2	57
129	A luminescent probe containing a tuftsin targeting vector coupled to a terbium complex. Chemical Communications, 2006, , 909.	2.2	54
130	Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. Journal of Neurochemistry, 2006, 98, 258-266.	2.1	147
131	Inactivation of Caspase-1 in Rodent Brain: A Novel Anticonvulsive Strategy. Epilepsia, 2006, 47, 1160-1168.	2.6	159
132	ADAMTS-1 and -4 are up-regulated following transient middle cerebral artery occlusion in the rat and their expression is modulated by TNF in cultured astrocytes. Brain Research, 2006, 1088, 19-30.	1.1	61
133	Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity. Journal of Neuroscience Research, 2006, 83, 385-391.	1.3	24
134	The Neurovascular Unit and the Key Role of Astrocytes in the Regulation of Cerebral Blood Flow. Cerebrovascular Diseases, 2006, 21, 137-138.	0.8	14
135	Interleukin-1 and neuronal injury. Nature Reviews Immunology, 2005, 5, 629-640.	10.6	864
136	Peripheral administration of interleukin-1Î² exacerbates ischaemic brain damage after transient focal ischaemia in mice. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S103-S103.	2.4	0
137	Anti-inflammatory modulators in stroke. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 59-67.	0.5	1
138	A dual role for interleukin-1 in LTP in mouse hippocampal slices. Journal of Neuroimmunology, 2003, 144, 61-67.	1.1	171
139	IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. Journal of Neuroimmunology, 2003, 139, 36-43.	1.1	42
140	Interleukinâ€1 in the Brain. Annals of the New York Academy of Sciences, 2003, 992, 39-47.	1.8	123
141	Inflammation in central nervous system injury. Philosophical Transactions of the Royal Society B: Biological Sciences, 2003, 358, 1669-1677.	1.8	301
142	The Interleukin-1 System: An Attractive and Viable Therapeutic Target in Neurodegenerative Disease. CNS and Neurological Disorders, 2003, 2, 293-302.	4.3	26
143	Sites and mechanisms of IL-1 action in ischemic and excitotoxic brain damage. , 2002, , 237-246.		0
144	Site-specific actions of interleukin-1 on excitotoxic cell death in the rat striatum. Brain Research, 2002, 926, 142-148.	1.1	19

#	Article	IF	Citations
145	Varied actions of proinflammatory cytokines on excitotoxic cell death in the rat central nervous system. Journal of Neuroscience Research, 2002, 67, 428-434.	1.3	18
146	Selective increases in cytokine expression in the rat brain in response to striatal injection of Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and interleukin-1. Molecular Brain Research, 2001, 93, 180-189.	2.5	16
147	Cytokines and acute neurodegeneration. Nature Reviews Neuroscience, 2001, 2, 734-744.	4.9	994
148	Cortical Death Caused by Striatal Administration of AMPA and Interleukin-1 is Mediated by Activation of Cortical NMDA Receptors. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 1409-1413.	2.4	11
149	Influence of corticotrophin releasing factor on neuronal cell death in vitro and in vivo. Brain Research, 2000, 881, 139-143.	1.1	25
150	Cortical cell death induced by IL-1 is mediated via actions in the hypothalamus of the rat. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5580-5585.	3.3	78
151	The Role of Proâ€•and Antiinflammatory Cytokines in Neurodegeneration. Annals of the New York Academy of Sciences, 2000, 917, 84-93.	1.8	54
152	Dissociation between the effects of interleukin-1 on excitotoxic brain damage and body temperature in the rat. Brain Research, 1999, 830, 32-37.	1.1	17
153	Interleukin-1Î² and interleukin-1 receptor antagonist do not affect glutamate release or calcium entry in rat striatal synaptosomes. Molecular Psychiatry, 1998, 3, 178-182.	4.1	17
154	Interleukin-1Î² and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. European Journal of Neuroscience, 1998, 10, 1188-1195.	1.2	150
155	Improved reperfusion following alternative surgical approach for experimental stroke in mice. F1000Research, 0, 9, 188.	0.8	1
156	A novel genotyping method to determine copy number in a mouse line commonly used for inducible transgene expression in brain and spinal cord. F1000Research, 0, 9, 1249.	0.8	0
157	A novel genotyping method to determine copy number in a mouse line commonly used for inducible transgene expression in brain and spinal cord. F1000Research, 0, 9, 1249.	0.8	0